Navigation Links
CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
Date:7/30/2008

Rite Aid to make available FIRST(R) Unit-of-Use prescription compounding

kits to its stores nationwide through Rite Aid distribution centers

WOBURN, Mass., July 30 /PRNewswire/ -- CutisPharma, Inc., an industry leader in developing products for prescription compounding, announced a partnership with Rite Aid Corporation (NYSE: RAD) that will make its innovative FIRST(R) Unit-of-Use Prescription Compounding Kits available for the approximately 27,000 pharmacists and pharmacy technicians at approximately 5,000 Rite Aid stores nationwide. Rite Aid will carry CutisPharma's FIRST(R) Unit-of-Use Prescription Compounding Kits nationwide in all its distribution centers, assuring constant availability. FIRST(R) products will allow Rite Aid the ability to offer compounding service to their customers and, for pharmacies already providing the service, increase the efficiency of their compounding offerings.

FIRST(R) Unit-of-Use Prescription-Compounding Kits are designed to provide an easy and time- saving solution for pharmacies. The pre-measured, pre- weighed components enable pharmacists to dispense the prescribed dosage accurately every time. A single NDC number assigned for the entire kit for each product greatly simplifies the third-party reimbursement process and reduces audit related adjustments. In addition, use of these kits facilitates compliance with the United States Pharmacopeia (USP) Chapter < 795 >.

"Our FIRST(R) Unit-of-Use compounding kits are user-friendly, save compounding time (by over 70%), and can be compounded by a Rite Aid pharmacist while the patient waits, increasing Rite Aid customer satisfaction and eliminating the need for an extra trip to the pharmacy," said Dr. Indu Muni, Chairman & CEO of CutisPharma.

Rite Aid Pharmacies will work with CutisPharma in notifying local physicians about the availability of compounding services at neighborhood Rite Aid stores using FIRST(R) kits.

It is estimated that approximately 30 million retail and hospital outpatient compounded prescriptions are prepared annually in the United States. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.

CutisPharma currently has nine proprietary prescription compounding kits in the market:
-- five strengths of progesterone suppository compounding kits;

-- two testosterone kits;

-- one hydrocortisone kit;

-- one Magic Mouthwash kit.

The company plans to introduce several more compounding kits in late 2008 and 2009.

About Rite Aid Corporation

Rite Aid Corporation is one of the nation's leading drugstore chains with approximately 5,000 stores in 31 states and the District of Columbia with fiscal 2008 annual sales of more than $24.3 billion. Information about Rite Aid, including corporate background and press releases, is available through the company's website at http://www.riteaid.com.

About CutisPharma, Inc.

CutisPharma, Inc., based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. A U.S. patent has been issued to the Company and additional patents are pending.

Contact:

James Nagle

V.P. Business Development

CutisPharma, Inc.

781-935-8141 x120

For more information please visit our website at http://www.cutispharma.com


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
2. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
3. BrainLAB Announces 510(k) FDA Clearance of Monte Carlo Dose Engine for Stereotactic Radiosurgery and Radiation Therapy
4. Align Technology Announces Second Quarter Fiscal 2008 Results
5. Monogram Announces 2008 Second Quarter Financial Results
6. Webcast Alert: Medial Saude S/A Announces Second Quarter 2008 Earnings Conference Call Webcast
7. The Quantum Group Announces Exclusive Screening of New PWeR(TM) System
8. Burgess Announces Expanded Software Partnership With Health Net
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Fast Radios Announces Publication of Two Way Radio Guide for Commercial Customers
11. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... engineers, and scientists from around the world, announces the launch of its newly ... and easy portal to research breakthroughs and trending news, vital information on upcoming ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote ... recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. ... to RMT technology that delivers HD, dynamic, streaming ultrasound images and video to ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is ... year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday ... clinic’s leading recovery program. , “We know it’s easy to get carried ...
(Date:1/19/2017)... Scotch Plains, NJ (PRWEB) , ... January 19, ... ... a board certified dermatologist by the American Board of Dermatology and fellowship trained ... Institute of the National Institutes of Health, Dr. Li completed his internship in ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate ... information has been condensed to a single page, maximizing usability and improving efficiency ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... 2017 James Gilbart ... Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European Oncology ... an article by James Gilbart and ...
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange , ... to announce that the first five replication studies ... have been published in eLife today. Despite intense ... the first practical evaluation of reproducibility rates that ... studies. Unlike other assessments of reproducibility, the results ...
Breaking Medicine Technology: